Erasca Stock Forecast, Price & News

Erasca (NASDAQ:ERAS) Frequently Asked Questions

Is Erasca a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Erasca stock.
View analyst ratings for Erasca or view top-rated stocks.

What stocks does MarketBeat like better than Erasca?

Wall Street analysts have given Erasca a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Erasca wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Erasca?

Erasca saw a increase in short interest in September. As of September 30th, there was short interest totaling 3,110,000 shares, an increase of 31.2% from the September 15th total of 2,370,000 shares. Based on an average daily trading volume, of 495,700 shares, the short-interest ratio is currently 6.3 days. Currently, 4.5% of the shares of the stock are short sold.
View Erasca's Short Interest.

When is Erasca's next earnings date?

Erasca is scheduled to release its next quarterly earnings announcement on Thursday, November 25th 2021.
View our earnings forecast for Erasca.

How were Erasca's earnings last quarter?

Erasca Inc (NASDAQ:ERAS) released its earnings results on Thursday, August, 26th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.49.
View Erasca's earnings history.

What price target have analysts set for ERAS?

5 Wall Street analysts have issued 12 month price targets for Erasca's shares. Their forecasts range from $25.00 to $28.00. On average, they anticipate Erasca's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price.
View analysts' price targets for Erasca or view top-rated stocks among Wall Street analysts.

Who are some of Erasca's key competitors?

Some companies that are related to Erasca include Grifols (GRFS), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), CureVac (CVAC), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Blueprint Medicines (BPMC), Allakos (ALLK), Cerevel Therapeutics (CERE) and HUTCHMED (HCM).
View all of ERAS's competitors.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

What is Erasca's stock symbol?

Erasca trades on the NASDAQ under the ticker symbol "ERAS."

Who are Erasca's major shareholders?

Erasca's stock is owned by a number of retail and institutional investors. Top institutional investors include Strs Ohio (0.00%).

Which institutional investors are buying Erasca stock?

ERAS stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio.

How do I buy shares of Erasca?

Shares of ERAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Erasca's stock price today?

One share of ERAS stock can currently be purchased for approximately $19.27.

How much money does Erasca make?

Erasca has a market capitalization of $2.34 billion.

How many employees does Erasca have?

Erasca employs 2,021 workers across the globe.

What is Erasca's official website?

The official website for Erasca is www.erasca.com.

How can I contact Erasca?

The company can be reached via phone at 858-465-6511 or via email at [email protected].